

# Contents

<b>1</b>	<b>Introduction . . . . .</b>	<b>1</b>
	Erika Jensen-Jarolim and Manuel L. Penichet	
<b>2</b>	<b>The Biology of IgE: Molecular Mechanism Restraining Potentially Dangerous High Serum IgE Titres In Vivo . . . . .</b>	<b>13</b>
	Gernot Achatz, Gertrude Achatz-Straussberger, Stefan Feichtner, Sebastian Koenigsberger, Stefan Lenz, Doris Peckl-Schmid, Nadja Zaborsky, and Marinus Lamers	
<b>3</b>	<b>The Biology of IgE: The Generation of High-Affinity IgE Antibodies . . . . .</b>	<b>37</b>
	Maria A. Curotto de Lafaille and Juan J. Lafaille	
<b>4</b>	<b>Epidemiological Evidence: IgE, Atopy, and Solid Tumors . . . . .</b>	<b>47</b>
	Michelle C. Turner	
<b>5</b>	<b>Epidemiological Evidence: IgE, Allergies, and Hematopoietic Malignancies . . . . .</b>	<b>79</b>
	Otoniel Martínez-Maza, Alan Duane Moreno, and Wendy Cozen	
<b>6</b>	<b>Mast Cells in Allergy and Tumor Disease . . . . .</b>	<b>137</b>
	Anna Wasiuk, Victor C. de Vries, Elizabeth C. Nowak, and Randolph J. Noelle	
<b>7</b>	<b>The IgE Antibody and Its Use in Cancer Immunotherapy . . . . .</b>	<b>159</b>
	Tracy R. Daniels, José A. Rodríguez, Elizabeth Ortiz-Sánchez, Gustavo Helguera, and Manuel L. Penichet	
<b>8</b>	<b>IgE Interacts with Potent Effector Cells Against Tumors: ADCC and ADCP . . . . .</b>	<b>185</b>
	Sophia N. Karagiannis, Frank O. Nestle, and Hannah J. Gould	
<b>9</b>	<b>IgE as Adjuvant in Tumor Vaccination . . . . .</b>	<b>215</b>
	Elisa A. Nigro, Antonio G. Siccardi, and Luca Vangelista	

<b>10 The Targets of IgE: Allergen-Associated and Tumor-Associated Molecular Patterns . . . . .</b>	<b>231</b>
Erika Jensen-Jarolim, Diana Mechtcheriakova, and Isabella Pali-Schoell	
<b>11 The Role of Th2-Mediated Anti-Tumor Immunity in Tumor Surveillance and Clearance . . . . .</b>	<b>255</b>
Luby Simson, Julia I. Ellyard, and Chris R. Parish	
<b>Subject Index . . . . .</b>	<b>277</b>